蒿甲醚-苯芴醇治疗选择非洲疟疾感染中恶性疟原虫多药耐药1(pfmdr1)拷贝数增加
在安哥拉北部本戈开展蒿甲醚-苯芴醇直接观察治疗 efficacy 试验,纳入100例2-10岁无并发症恶性疟疾患者,住院治疗并随访42天。观察到治疗后基因扩增显著选择,基线pfmdr1×N qPCR评分≥1.4与第42天疗效降低相关(79% vs 97%单拷贝)。所有感染均为pfmdr1 N86携带者,未发现pfk13突变。
要点
- 蒿甲醚-苯芴醇治疗后出现pfmdr1基因扩增的显著选择。
- 基线pfmdr1×N评分≥1.4者第42天疗效79%,单拷贝者97%。
- 所有感染为pfmdr1 N86携带者,未发现pfk13突变。
核心结论
- 本研究提示pfmdr1×N可作为非洲恶性疟原虫体内对苯芴醇反应的标志物,并表明治疗前pfmdr1×N评分≥1.4的感染患者是蒿甲醚-苯芴醇疗效降低的群体。
研究设计与样本
- 在安哥拉北部本戈开展基于直接观察蒿甲醚-苯芴醇治疗的疗效试验,纳入100例2-10岁无并发症恶性疟疾患者,治疗期间住院并随访42天。
- 采用pfmsp1/2加glurp进行PCR校正,分析考虑2或3个一致标志物。
- 通过定量PCR检测pfmdr1拷贝数(pfmdr1×N),并构建体外克隆混合物以确定qPCR拷贝数评分与感染内pfmdr1×N实际定量比例的关系。
主要发现
- 观察到治疗后基因扩增的显著选择,提示其在寄生虫体内对该药反应中的作用。
- pfmdr1×2 qPCR评分1.3、1.4和1.5分别对应15%、25%和35%的感染内比例。
- 基线感染评分≥1.4的患者与蒿甲醚-苯芴醇第42天疗效降低相关(79% vs 97%单拷贝pfmdr1)。
- 所有感染均为pfmdr1 N86携带者,未发现pfk13突变。
关键数值与推荐
- 基线pfmdr1×N qPCR评分≥1.4者第42天疗效79%,单拷贝pfmdr1者97%。
- pfmdr1×2 qPCR评分1.3对应15%感染内比例,1.4对应25%,1.5对应35%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Decreased efficacy of artemether-lumefantrine, the globally most used antimalarial, has recently emerged in Africa. METHODS: An efficacy trial was carried out based on directly observed artemether-lumefantrine therapy at Bengo, Northern Angola. One-hundred Plasmodium falciparum uncomplicated malaria patients (2-10 years old) were enrolled, hospitalized for the treatment period, and followed up for 42 days. Polymerase chain reaction (PCR) correction was performed with pfmsp1/2 plus glurp, with analysis considering 2 or 3 coincident markers. Infections were tested by quantitative PCR (qPCR) for pfmdr1 copy number (pfmdr1×N), a potential P. falciparum marker of lumefantrine resistance previously identified in the region. In vitro clone mixtures were built and used to determine the relation between qPCR copy number scores and actual intrainfection quantitative fractions of pfmdr1×N. RESULTS: We observed a significant posttreatment selection of gene amplification, suggesting a role in the parasite in vivo response to this drug. pfmdr1×2 qPCR scores of 1.3, 1.4, and 1.5 were determined to correspond to 15%, 25%, and 35% intrainfection rates. Patients carrying infections with a score ≥1.4 at baseline were linked to decreased artemether-lumefantrine day 42 efficacy (79% vs 97% single-copy pfmdr1). All infections were pfmdr1 N86 carriers and no pfk13 mutations were found. CONCLUSIONS: Our study suggests pfmdr1×N as a marker of P. falciparum in vivo response to lumefantrine in Africa, while indicating patients carrying infections with a pretreatment pfmdr1×N score ≥1.4 before treatment are a group experiencing decreased artemether-lumefantrine performance.
引用
- Fançony C, Fortes-Gabriel E, Zage F, et al. Artemether-Lumefantrine Treatment Selects Plasmodium falciparum Multidrug Resistance 1 (pfmdr1) Increased Copy Number Among African Malaria Infections. J Infect Dis. 2025. PMID: 40138574. doi:10.1093/infdis/jiaf155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。